Recce Pharmaceuticals

Sydney, Australia Founded: 2007 • Age: 19 yrs Listed
Antibiotics for drug-resistant bacteria and cancer treatments are developed.

About Recce Pharmaceuticals

Recce Pharmaceuticals is a publicly listed company based in Sydney (Australia) founded in 2007. Antibiotics for drug-resistant bacteria and cancer treatments are developed. It operates on a HealthTech model. Its chief executive, as recorded, is James Graham. Recce Pharmaceuticals offers products and services including Synthetic Anti-Infectives, Intravenous Sepsis Treatment, and Topical ABSSSI Treatment. Its focus areas include Pharmaceuticals and Anti-Infectives. Its legal entity is Recce Pharmaceuticals Ltd.

Company details

Recce Pharmaceuticals Ltd is engaged in the development of a new class of synthetic anti-infectives aimed at addressing the global challenge of antibiotic-resistant superbugs. The company operates in the healthcare sector, focusing on solutions for bacterial and viral infections. Multiple clinical indications and formulations are being pursued, including Phase I and II trials, as well as a registrational Phase III trial in Indonesia. Their proprietary anti-infectives are designed with a universal mechanism of action to overcome hyper-cellular mutations in bacteria and viruses.

  • Headquarters Sydney, Australia
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website recce.com.au
  • Social LinkedIn X Instagram YouTube
  • Legal Name Recce Pharmaceuticals Ltd
Operational Areas
Key Metrics
  • Net Profit
    -$10.3 M (USD)
    30.18
    as on Jun 30, 2026
  • EBITDA
    -$15.71 M (USD)
    17.51
    as on Jun 30, 2026
  • Latest Funding Round
    $4.76M (USD), Post-IPO

    Jun 2025

Products & Services of Recce Pharmaceuticals

Recce Pharmaceuticals offers a comprehensive portfolio of products and services, including Synthetic Anti-Infectives, Intravenous Sepsis Treatment, and Topical ABSSSI Treatment.

Synthetic Anti-Infectives
Pharmaceuticals

Synthetic anti-infectives are developed to combat resistant bacteria.

Intravenous Sepsis Treatment
Clinical Candidates

Intravenous treatment for sepsis is being clinically tested.

Topical ABSSSI Treatment
Clinical Candidates

Topical treatment for ABSSSI is under clinical development.

Apps and channels of Recce Pharmaceuticals

its YouTube channel Recce Pharmaceuticals has 153 subscribers and 30 videos.

Recce Pharmaceuticals
YouTube 153 subscribers 30 videos Science & Technology
Open channel

Videos from Recce Pharmaceuticals

The most watched videos on Recce Pharmaceuticals's YouTube channel, Recce Pharmaceuticals (153 subscribers). Click a video to play it here.

Ausbiz Interview - Recce Pharmaceuticals (RCE)
1.5K views
Recce Pharmaceuticals | April 2025 Investor Webinar
511 views
Ausbiz Interview - Recce Pharmaceuticals CEO James Graham
413 views
Clinical Milestones Webinar
347 views

More on Recce Pharmaceuticals.

Funding Insights of Recce Pharmaceuticals

  • Total Rounds 5
  • Last Round Post-IPO β€” $4.76M
  • First Round $1.28M

    (Feb 2019)

All 5 funding rounds of Recce Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2025$4.76MPost-IPO––
–
Apr 2025$10.11MPost-IPO––
–
Sep 2020$20.11MPost-IPO––
–
Oct 2019$4.56MPost-IPO––
–
Feb 2019$1.28MPost-IPO––
–

People of Recce Pharmaceuticals

15 people are tracked at Recce Pharmaceuticals (6 in leadership, 4 in board & advisors, 5 in team).

NameRoleGroup
James Graham
CEOLeadership
Justin Reynolds
Chief Financial OfficerLeadership
Michele Dilizia
Executive Director & Chief Scientific OfficerLeadership
Andre Serobian
Commercial DirectorLeadership
Cherise A.
Vice President Of Corporate AffairsLeadership
Peter McCray
Head Of OperationsLeadership
John Prendergast
Non-Executive ChairmanBoard & advisors
Alan Dunton
Non-Executive DirectorBoard & advisors
David Bowers
Chair of Clinical Advisory CommitteeBoard & advisors
Philip Sutton
Clinical Advisory Committee MemberBoard & advisors
Daniel Astudillo
Marketing ManagerTeam
Simone Messenger
Executive AssistantTeam
Thomas Skinner
Senior Marketing ManagerTeam
Michelle Corke
Office ManagerTeam
Amanda Giovanelli
Marketing SpecialistTeam
Premium access

Complete people profiles for Recce Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Recce Pharmaceuticals

Recce Pharmaceuticals is a publicly listed company on the ASX with ticker symbol RCE in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date15 Jan 2016
  • Listed onASX: RCE
  • Listed entityRECCE PHARMACEUTICALS LTD
  • Exchange sectorHealth technology
  • ISINAU000000RCE5
  • Share price0.29 AUD (+9.43% on the day) · 2026-10-14
  • Market capitalisation81,029,059.00 AUD
  • EPS (diluted, trailing year)-0.05 AUD
  • Volume (last session)43,027

Financials of Recce Pharmaceuticals

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2026-15.0M AUD-22.8M AUD
2025-21.4M AUD-27.6M AUD
2024-17.7M AUD-21.7M AUD
2023-13.1M AUD-17.1M AUD
2022-11.0M AUD-14.0M AUD
Premium access

Detailed financial statements for Recce Pharmaceuticals

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Recce Pharmaceuticals

4 dated milestones of Recce Pharmaceuticals across 18 years, from founding to its latest funding, stage changes and deals.

  1. Founded Recce Pharmaceuticals is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $1.3M.
  4. Funding Latest funding round, Post-IPO, of $4.8M.

Web traffic of Recce Pharmaceuticals

The website of Recce Pharmaceuticals (recce.com.au) receives about 3.4K visits a month.

  • Monthly visits
    3.4K

    ▼ 45.4% vs previous month

Similar websites

Websites whose visitors overlap most with Recce Pharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
ginzalimited.com
100%
3.6K#4,922,195View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Recce Pharmaceuticals

Premium access

Complete news archive for Recce Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Recce Pharmaceuticals

Recce Pharmaceuticals was founded in 2007 and raised its 1st funding round 12 years after it was founded.

Recce Pharmaceuticals is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.

James Graham is the CEO of Recce Pharmaceuticals, as recorded in our data.

Recce Pharmaceuticals Ltd is engaged in the development of a new class of synthetic anti-infectives aimed at addressing the global challenge of antibiotic-resistant superbugs. The company operates in the healthcare sector, focusing on solutions for bacterial and viral infections. Multiple clinical indications and formulations are being pursued, including Phase I and II trials, as well as a registrational Phase III trial in Indonesia. Their proprietary anti-infectives are designed with a universal mechanism of action to overcome hyper-cellular mutations in bacteria and viruses.

Recce Pharmaceuticals offers Synthetic Anti-Infectives, Intravenous Sepsis Treatment, and Topical ABSSSI Treatment.

Yes, Recce Pharmaceuticals is publicly traded on ASX under the ticker symbol RCE.

Recce Pharmaceuticals operates through Recce Pharmaceuticals Ltd.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available